<?xml version='1.0' encoding='utf-8'?>
<document id="31182531"><sentence text="Bedaquiline Eliminates Bactericidal Activity of β-Lactams against Mycobacterium abscessus."><entity charOffset="0-11" id="DDI-PubMed.31182531.s1.e0" text="Bedaquiline" /></sentence><sentence text="The β-lactams imipenem and cefoxitin are used for the treatment of Mycobacterium abscessus lung infections"><entity charOffset="4-22" id="DDI-PubMed.31182531.s2.e0" text="β-lactams imipenem" /><entity charOffset="27-36" id="DDI-PubMed.31182531.s2.e1" text="cefoxitin" /><pair ddi="false" e1="DDI-PubMed.31182531.s2.e0" e2="DDI-PubMed.31182531.s2.e0" /><pair ddi="false" e1="DDI-PubMed.31182531.s2.e0" e2="DDI-PubMed.31182531.s2.e1" /></sentence><sentence text=" Here, we show that these cell wall synthesis inhibitors trigger a lethal bacterial ATP burst by increasing oxidative phosphorylation" /><sentence text=" Cotreatment of M" /><sentence text=" abscessus with the antimycobacterial ATP synthase inhibitor bedaquiline suppresses this ATP burst and eliminates the bactericidal activity of β-lactams"><entity charOffset="38-41" id="DDI-PubMed.31182531.s5.e0" text="ATP" /><entity charOffset="61-72" id="DDI-PubMed.31182531.s5.e1" text="bedaquiline" /><entity charOffset="89-92" id="DDI-PubMed.31182531.s5.e2" text="ATP" /><pair ddi="false" e1="DDI-PubMed.31182531.s5.e0" e2="DDI-PubMed.31182531.s5.e0" /><pair ddi="false" e1="DDI-PubMed.31182531.s5.e0" e2="DDI-PubMed.31182531.s5.e1" /><pair ddi="false" e1="DDI-PubMed.31182531.s5.e0" e2="DDI-PubMed.31182531.s5.e2" /><pair ddi="false" e1="DDI-PubMed.31182531.s5.e1" e2="DDI-PubMed.31182531.s5.e1" /><pair ddi="false" e1="DDI-PubMed.31182531.s5.e1" e2="DDI-PubMed.31182531.s5.e2" /></sentence><sentence text=" Thus, the addition of bedaquiline to β-lactam-containing regimes may negatively affect treatment outcome"><entity charOffset="23-34" id="DDI-PubMed.31182531.s6.e0" text="bedaquiline" /></sentence><sentence text="" /></document>